Akebia Therapeutics (Cincinnati, OH) a clinical-stage biopharmaceutical company focused on the development of small-molecules for anemia and vascular disease, closed a $16M Series A bringing the total financing to $25M. Participants include Novartis Venture Fund, Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners and Sigvion Capital.

CerviLenz (Chagrin Falls, OH) a commercial-stage developer of a diagnostic single-use medical device for measuring cervical length to determine the risk of pre-term birth in pregnant women, closed a $4M Series A financing. Participants include Arboretum Ventures and Chrysalis Ventures.